2. Search Result
Search Result
Results for "

926

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Inhibitory Antibodies

4

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16510
    UNC926

    		Epigenetic Reader Domain Cancer
    UNC926 is a methyl-lysine (Kme) reader domain inhibitor that inhibits L3MBTL1 with an IC50 of 3.9 μM .
    UNC926
  • HY-16587
    Saridegib

    IPI-926; Patidegib

    		 Smo Cancer
    Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
    Saridegib
  • HY-160259
    VEGFR-2-IN-39

    		PROTACs VEGFR Cardiovascular Disease
    VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting VEGFR-2 (IC50: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC50 of 38.65 µM .
    VEGFR-2-IN-39
  • HY-122006
    NPD926

    		Reactive Oxygen Species (ROS) Cancer
    NPD926 is a small molecule that targets glutathione and induces cancer cell death. The Xc - system and glutathione are therapeutic targets in cancer. NPD926 causes cellular glutathione depletion and subsequent generation of reactive oxygen species (ROS), thereby sensitizing fibroblasts to Xc - system inhibitors. NPD926 is a ROS inducer with anticancer activity. .
    NPD926
  • HY-116605
    GSK926

    		Histone Methyltransferase Cancer
    GSK926 (compound 3) is a selective histone lysine methyltransferase EZH2 inhibitor (IC50=0.02 μM; Ki=7.9 nM), with SAM-competitive and cell-active properties. GSK926 can be used in cancer research .
    GSK926
  • HY-16510A
    UNC926 hydrochloride

    		Epigenetic Reader Domain Cancer
    UNC926 hydrochloride is a methyl-lysine (Kme) reader domain inhibitor that inhibits L3MBTL1 with an IC50 of 3.9 μM .
    UNC926 hydrochloride
  • HY-P991371
    PF-06478924

    PF-06664178 antibody; RN926

    		TROP2 Cancer
    PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
    PF-06478924
  • HY-16587A
    Saridegib hydrochloride

    IPI 926 hydrochloride; Patidegib hydrochloride

    		 Smo Cancer
    Saridegib hydrochloride is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
    Saridegib hydrochloride
  • HY-146368
    PROTAC VEGFR-2 degrader-1

    		PROTACs VEGFR Cancer
    PROTAC VEGFR-2 degrader-1（PROTAC-1）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC50> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC50> 100 μM) .
    PROTAC VEGFR-2 degrader-1
  • HY-146369
    PROTAC VEGFR-2 degrader-2

    		PROTACs VEGFR Cancer
    PROTAC VEGFR-2 degrader-2（PROTAC-4）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC50> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC50> 100μM) .
    PROTAC VEGFR-2 degrader-2
  • HY-RS02276
    CD8B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CD8B Human Pre-designed siRNA Set A contains three designed siRNAs for CD8B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD8B Human Pre-designed siRNA Set A
    CD8B Human Pre-designed siRNA Set A
  • HY-135457
    JMS-053

    		Phosphatase Cancer
    JMS-053 is a potent, selective and reversible PTP4A inhibitor, with IC50s of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM, and 207.6 nM for PTP4A1, PTP4A2, PTP4A3, CDC25B, and DUSP3, respectively. JMS-053 can inhibit cancer cell migration and spheroid growth in vitro, attenuate in vivo ovarian tumor growth .
    JMS-053
  • HY-173064
    DS-103

    		HDAC Parasite Infection Cancer
    DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin (HY-17394) resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis .
    DS-103

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: